Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter June 1, 2005

Apolipoprotein E Polymorphism and Serum Concentration in Alzheimer's Disease in Nine European Centres: the ApoEurope Study

Gerard Siest, Philippe Bertrand, Bin Qin, Bernard Herbeth, Jean-Marie Serot, Luis Masana, Josep Ribalta, A. Peter Passmore, Alun Evans, Maurizio Ferrari, Massimo Franceschi, James Shepherd, Marina Cuchel, Ulrike Beisiegel, Katrin Zuchowsky, Ana Stavljenic Rukavina, Jadranka Sertic, Marina Stojanov, Vladimir Kostic, Angel Mitrevski, Vera Petrova, Catherine Sass, Aksam Merched, Jukka T. Salonen, Laurence Tiret, Sophie Visvikis and the ApoEurope group13
From the journal


As part of the ApoEurope Project, apolipoprotein E (apo E) common polymorphism and serum concentration were determined in 489 Alzheimer's disease patients and 429 controls. Patients and controls were recruited through nine centres in eight European countries. Age, sex ratios and education levels of both case and control populations were similar, although discrete differences appeared between centres. The prevalence of the ε4 allele was higher in Alzheimer's disease than in controls (increased by 140%), while serum apo E concentration was lower by 11.2% (p<0.001). In addition, serum total cholesterol and triglyceride concentrations were lower in Alzheimer's disease (p<0.001), while that of apo AI was not affected. The decrease in serum apo E concentration was not accounted for by the ε4 allele, age or gender, suggesting that apo E concentration might represent an additional risk factor for Alzheimer's disease, complementary and independent of the ε4 allele. Further analysis will be aimed at determining whether the quantitative link between apo E concentration and Alzheimer's disease occurs through the effect of apo E genotype on lipid parameters or by other mechanisms.

Published Online: 2005-06-01
Published in Print: 2000-08-21

Copyright © 2000 by Walter de Gruyter GmbH & Co. KG